What's expected at ESMO 2024?

0 Phase 3 trials are estimated to complete within the conference window. Focus areas: Oncology — Phase 3 readouts (European).

How is this list generated?

Phase 3 trials with primary completion dates in the 4 months leading up to + 1 month after the conference, sourced from ClinicalTrials.gov. Not every trial will present at the conference — but most pivotal data in the area typically debuts within this window.

ESMO 2024 — European Society for Medical Oncology Congress

European counterpart to ASCO. Pivotal Phase 3 data, especially in solid tumours, often debuts here for European-sponsor trials.

Months 9–10, 2024 Various (Berlin, Madrid, Barcelona, Paris) Oncology — Phase 3 readouts (European) Archive

Phase 3 watch list (0 trials in the ±2-month window)

Trials with primary completion in the months leading up to + just after the conference — the typical window for pivotal data presentations.

No Phase 3 trials with completion in this window.

Recent / nearby approvals in the area

No nearby approvals in the area.

Subscribe to conference alerts

Get every Phase 3 readout + approval in this therapeutic area:

Phase 3 readouts RSS
Recent approvals RSS
Build a custom filter

All ESMO years + other conferences
Full Phase 3 readout calendar
Upcoming PDUFA dates
CI briefs

ESMO 2024 — European Society for Medical Oncology Congress

Phase 3 watch list (0 trials in the ±2-month window)

Recent / nearby approvals in the area

Subscribe to conference alerts

Related